Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 14 de 14
Filter
Add more filters










Publication year range
1.
Br J Ophthalmol ; 107(7): 980-986, 2023 Jul.
Article in English | MEDLINE | ID: mdl-35115301

ABSTRACT

BACKGROUND: Age-related macular degeneration (AMD) in its late stages is a leading cause of sight loss in developed countries. Some previous studies have suggested that metformin may be associated with a reduced risk of developing AMD, but the evidence is inconclusive. AIMS: To explore the relationship between metformin use and development of AMD among patients with type 2 diabetes in the UK. METHODS: A large, population-based retrospective open cohort study with a time-dependent exposure design was carried out using IQVIA Medical Research Data, 1995-2019. Patients aged ≥40 with diagnosed type 2 diabetes were included.The exposed group was those prescribed metformin (with or without any other antidiabetic medications); the comparator (unexposed) group was those prescribed other antidiabetic medications only. The exposure status was treated as time varying, collected at 3-monthly time intervals.Extended Cox proportional hazards regression was used to calculate the adjusted HRs for development of the outcome, newly diagnosed AMD. RESULTS: A total of 173 689 patients, 57% men, mean (SD) age 62.8 (11.6) years, with incident type 2 diabetes and a record of one or more antidiabetic medications were included in the study. Median follow-up was 4.8 (IQR 2.3-8.3, range 0.5-23.8) years. 3111 (1.8%) patients developed AMD. The adjusted HR for diagnosis of AMD was 1.02 (95% CI 0.92 to 1.12) in patients prescribed metformin (with or without other antidiabetic medications) compared with those prescribed any other antidiabetic medication only. CONCLUSION: We found no evidence that metformin was associated with risk of AMD in primary care patients requiring treatment for type 2 diabetes.


Subject(s)
Diabetes Mellitus, Type 2 , Macular Degeneration , Metformin , Male , Humans , Female , Metformin/adverse effects , Diabetes Mellitus, Type 2/complications , Diabetes Mellitus, Type 2/drug therapy , Retrospective Studies , Cohort Studies , Hypoglycemic Agents/adverse effects , Macular Degeneration/diagnosis , Macular Degeneration/drug therapy , Macular Degeneration/epidemiology , Risk Factors
3.
Br J Clin Pharmacol ; 88(9): 4199-4210, 2022 09.
Article in English | MEDLINE | ID: mdl-35474585

ABSTRACT

AIMS: Several observational studies have examined the potential protective effect of angiotensin-converting enzyme inhibitor (ACE-I) use on the risk of age-related macular degeneration (AMD) and have reported contradictory results owing to confounding and time-related biases. We aimed to assess the risk of AMD in a base cohort of patients aged 40 years and above with hypertension among new users of ACE-I compared to an active comparator cohort of new users of calcium channel blockers (CCB) using data obtained from IQVIA Medical Research Data, a primary care database in the UK. METHODS: In this study, 53 832 and 43 106 new users of ACE-I and CCB were included between 1995 and 2019, respectively. In an on-treatment analysis, patients were followed up from the time of index drug initiation to the date of AMD diagnosis, loss to follow-up, discontinuation or switch to the comparator drug. A comprehensive range of covariates were used to estimate propensity scores to weight and match new users of ACE-I and CCB. Standardized mortality ratio weighted Cox proportional hazards model was used to estimate hazard ratios of developing AMD. RESULTS: During a median follow-up of 2 years (interquartile range 1-5 years), the incidence rate of AMD was 2.4 (95% confidence interval 2.2-2.6) and 2.2 (2.0-2.4) per 1000 person-years among the weighted new users of ACE-I and CCB, respectively. There was no association of ACE-I use on the risk of AMD compared to CCB use in either the propensity score weighted or matched, on-treatment analysis (adjusted hazard ratio: 1.07 [95% confidence interval 0.90-1.27] and 0.87 [0.71-1.07], respectively). CONCLUSION: We found no evidence that the use of ACE-I is associated with risk of AMD in patients with hypertension.


Subject(s)
Hypertension , Macular Degeneration , Angiotensin-Converting Enzyme Inhibitors/adverse effects , Calcium Channel Blockers/therapeutic use , Cohort Studies , Humans , Hypertension/complications , Hypertension/drug therapy , Hypertension/epidemiology , Incidence , Macular Degeneration/drug therapy , Macular Degeneration/epidemiology
4.
NPJ Genom Med ; 7(1): 14, 2022 Feb 23.
Article in English | MEDLINE | ID: mdl-35197474

ABSTRACT

Single-stranded ends of double-stranded DNA (jagged ends) are more abundant in urinary DNA than in plasma DNA. However, the lengths of jagged ends in urinary DNA remained undetermined, as a previous method used for urinary DNA jagged end sequencing analysis (Jag-seq) relied on unmethylation at CpG sites, limiting the resolution. Here, we performed high-resolution Jag-seq analysis using methylation at non-CpG cytosine sites, allowing determination of exact length of jagged ends. The urinary DNA bore longer jagged ends (~26-nt) than plasma DNA (~17-nt). The jagged end length distribution displayed 10-nt periodicities in urinary DNA, which were much less observable in plasma DNA. Amplitude of the 10-nt periodicities increased in patients with renal cell carcinoma. Heparin treatment of urine diminished the 10-nt periodicities. The urinary DNA jagged ends often extended into nucleosomal cores, suggesting potential interactions with histones. This study has thus advanced our knowledge of jagged ends in urine DNA.

5.
Genome Res ; 31(11): 2008-2021, 2021 11.
Article in English | MEDLINE | ID: mdl-34470801

ABSTRACT

The effects of DNASE1L3 or DNASE1 deficiency on cell-free DNA (cfDNA) methylation were explored in plasma of mice deficient in these nucleases and in DNASE1L3-deficient humans. Compared to wild-type cfDNA, cfDNA in DNASE1L3-deficient mice was significantly hypomethylated, while cfDNA in DNASE1-deficient mice was hypermethylated. The cfDNA hypomethylation in DNASE1L3-deficient mice was due to increased fragmentation and representation from open chromatin regions (OCRs) and CpG islands (CGIs). These findings were absent in DNASE1-deficient mice, demonstrating the preference of DNASE1 to cleave in hypomethylated OCRs and CGIs. We also observed a substantial decrease of fragment ends at methylated CpGs in the absence of DNASE1L3, thereby demonstrating that DNASE1L3 prefers to cleave at methylated CpGs. Furthermore, we found that methylation levels of cfDNA varied by fragment size in a periodic pattern, with cfDNA of specific sizes being more hypomethylated and enriched for OCRs and CGIs. These findings were confirmed in DNASE1L3-deficient human cfDNA. Thus, we have found that nuclease-mediated cfDNA fragmentation markedly affects cfDNA methylation level on a genome-wide scale. This work provides a foundational understanding of the relationship between methylation, nuclease biology, and cfDNA fragmentation.


Subject(s)
Cell-Free Nucleic Acids , DNA Fragmentation , Endodeoxyribonucleases , Animals , Cell-Free Nucleic Acids/genetics , Cell-Free Nucleic Acids/metabolism , Chromatin , CpG Islands/genetics , DNA Methylation , Endodeoxyribonucleases/genetics , Humans , Mice
6.
Trends Genet ; 37(8): 758-770, 2021 08.
Article in English | MEDLINE | ID: mdl-34006390

ABSTRACT

Cell-free DNA (cfDNA) is a widely used noninvasive biomarker for diagnosis and prognosis of multiple disease states. Emerging evidence suggests that cfDNA might not just be passive waste products of cell death but could have a physiological and pathological function in inflammation and autoimmunity. The balance of cfDNA generation and clearance may thus be vital in health and disease. In particular, plasma nuclease activity has been linked to multiple pathologies including cancer and systemic lupus erythematosus (SLE) and associated with profound changes in the nonrandom fragmentation of cfDNA. Lastly, in this review, we explore the effects of DNA fragmentation factor B (DFFB), DNASE1L3, and DNASE1 on cfDNA levels and their fragmentomic profiles, and what these recent insights reveal about the biology of cfDNA.


Subject(s)
Cell-Free Nucleic Acids/genetics , Deoxyribonuclease I/genetics , Deoxyribonucleases/genetics , Endodeoxyribonucleases/genetics , Poly-ADP-Ribose Binding Proteins/genetics , Autoimmunity/genetics , Cell-Free Nucleic Acids/blood , DNA Fragmentation , Deoxyribonuclease I/blood , Deoxyribonucleases/blood , Endodeoxyribonucleases/blood , Humans , Inflammation/blood , Inflammation/genetics , Inflammation/pathology , Poly-ADP-Ribose Binding Proteins/blood
7.
Science ; 372(6538)2021 04 09.
Article in English | MEDLINE | ID: mdl-33833097

ABSTRACT

Liquid biopsies that analyze cell-free DNA in blood plasma are used for noninvasive prenatal testing, oncology, and monitoring of organ transplant recipients. DNA molecules are released into the plasma from various bodily tissues. Physical and molecular features of cell-free DNA fragments and their distribution over the genome bear information about their tissues of origin. Moreover, patterns of DNA methylation of these molecules reflect those of their tissue sources. The nucleosomal organization and nuclease content of the tissue of origin affect the fragmentation profile of plasma DNA molecules, such as fragment size and end motifs. Besides double-stranded linear fragments, other topological forms of cell-free DNA also exist-namely circular and single-stranded molecules. Enhanced by these features, liquid biopsies hold promise for the noninvasive detection of tissue-specific pathologies with a range of clinical applications.


Subject(s)
Cell-Free Nucleic Acids/blood , Cell-Free Nucleic Acids/genetics , DNA Fragmentation , DNA Methylation , DNA/blood , DNA/genetics , Liquid Biopsy , Animals , Biomarkers/blood , DNA, Circular/blood , DNA, Mitochondrial/blood , DNA, Neoplasm/blood , DNA, Neoplasm/genetics , Deoxyribonucleases/metabolism , Epigenesis, Genetic , Female , Fetus , Humans , Pregnancy , Transplants
8.
Am J Hum Genet ; 107(5): 882-894, 2020 11 05.
Article in English | MEDLINE | ID: mdl-33022220

ABSTRACT

Plasma DNA fragmentomics is an emerging area in cell-free DNA diagnostics and research. In murine models, it has been shown that the extracellular DNase, DNASE1L3, plays a role in the fragmentation of plasma DNA. In humans, DNASE1L3 deficiency causes familial monogenic systemic lupus erythematosus with childhood onset and anti-dsDNA reactivity. In this study, we found that human patients with DNASE1L3 disease-associated gene variations showed aberrations in size and a reduction of a "CC" end motif of plasma DNA. Furthermore, we demonstrated that DNA from DNASE1L3-digested cell nuclei showed a median length of 153 bp with CC motif frequencies resembling plasma DNA from healthy individuals. Adeno-associated virus-based transduction of Dnase1l3 into Dnase1l3-deficient mice restored the end motif profiles to those seen in the plasma DNA of wild-type mice. Our findings demonstrate that DNASE1L3 is an important player in the fragmentation of plasma DNA, which appears to act in a cell-extrinsic manner to regulate plasma DNA size and motif frequency.


Subject(s)
DNA/genetics , Endodeoxyribonucleases/genetics , Lupus Erythematosus, Systemic/genetics , Mutation , Animals , Case-Control Studies , DNA/blood , DNA Fragmentation , Dependovirus/genetics , Dependovirus/metabolism , Disease Models, Animal , Endodeoxyribonucleases/deficiency , Endodeoxyribonucleases/metabolism , Genetic Therapy , Genetic Vectors/chemistry , Genetic Vectors/metabolism , Humans , Lupus Erythematosus, Systemic/enzymology , Lupus Erythematosus, Systemic/pathology , Mice , Mice, Transgenic , Substrate Specificity , Transduction, Genetic
10.
Am J Hum Genet ; 106(2): 202-214, 2020 02 06.
Article in English | MEDLINE | ID: mdl-32004449

ABSTRACT

Cell-free DNA (cf.DNA) is a powerful noninvasive biomarker for cancer and prenatal testing, and it circulates in plasma as short fragments. To elucidate the biology of cf.DNA fragmentation, we explored the roles of deoxyribonuclease 1 (DNASE1), deoxyribonuclease 1 like 3 (DNASE1L3), and DNA fragmentation factor subunit beta (DFFB) with mice deficient in each of these nucleases. By analyzing the ends of cf.DNA fragments in each type of nuclease-deficient mice with those in wild-type mice, we show that each nuclease has a specific cutting preference that reveals the stepwise process of cf.DNA fragmentation. Essentially, we demonstrate that cf.DNA is generated first intracellularly with DFFB, intracellular DNASE1L3, and other nucleases. Then, cf.DNA fragmentation continues extracellularly with circulating DNASE1L3 and DNASE1. With the use of heparin to disrupt the nucleosomal structure, we also show that the 10 bp periodicity originates from the cutting of DNA within an intact nucleosomal structure. Altogether, this work establishes a model of cf.DNA fragmentation.


Subject(s)
Cell-Free Nucleic Acids/metabolism , Chromatin/metabolism , DNA Fragmentation , Deoxyribonuclease I/physiology , Deoxyribonucleases/physiology , Endodeoxyribonucleases/physiology , Nucleosomes/metabolism , Poly-ADP-Ribose Binding Proteins/physiology , Animals , Cell-Free Nucleic Acids/genetics , Chromatin/genetics , Female , Male , Mice , Mice, Knockout , Nucleosomes/genetics
11.
PLoS One ; 10(7): e0132672, 2015.
Article in English | MEDLINE | ID: mdl-26200659

ABSTRACT

The obesity epidemic in the U.S. has led to extensive research into potential contributing dietary factors, especially fat and fructose. Recently, increased consumption of soybean oil, which is rich in polyunsaturated fatty acids (PUFAs), has been proposed to play a causal role in the epidemic. Here, we designed a series of four isocaloric diets (HFD, SO-HFD, F-HFD, F-SO-HFD) to investigate the effects of saturated versus unsaturated fat, as well as fructose, on obesity and diabetes. C57/BL6 male mice fed a diet moderately high in fat from coconut oil and soybean oil (SO-HFD, 40% kcal total fat) showed statistically significant increases in weight gain, adiposity, diabetes, glucose intolerance and insulin resistance compared to mice on a diet consisting primarily of coconut oil (HFD). They also had fatty livers with hepatocyte ballooning and very large lipid droplets as well as shorter colonic crypt length. While the high fructose diet (F-HFD) did not cause as much obesity or diabetes as SO-HFD, it did cause rectal prolapse and a very fatty liver, but no balloon injury. The coconut oil diet (with or without fructose) increased spleen weight while fructose in the presence of soybean oil increased kidney weight. Metabolomics analysis of the liver showed an increased accumulation of PUFAs and their metabolites as well as γ-tocopherol, but a decrease in cholesterol in SO-HFD. Liver transcriptomics analysis revealed a global dysregulation of cytochrome P450 (Cyp) genes in SO-HFD versus HFD livers, most notably in the Cyp3a and Cyp2c families. Other genes involved in obesity (e.g., Cidec, Cd36), diabetes (Igfbp1), inflammation (Cd63), mitochondrial function (Pdk4) and cancer (H19) were also upregulated by the soybean oil diet. Taken together, our results indicate that in mice a diet high in soybean oil is more detrimental to metabolic health than a diet high in fructose or coconut oil.


Subject(s)
Diabetes Mellitus/etiology , Fructose/adverse effects , Liver/drug effects , Obesity/etiology , Plant Oils/adverse effects , Soybean Oil/adverse effects , Animals , Coconut Oil , Cytochrome P-450 Enzyme System/genetics , Diabetes Mellitus/epidemiology , Diabetes Mellitus/genetics , Dietary Fats/adverse effects , Gene Expression Regulation/drug effects , Insulin Resistance , Liver/metabolism , Liver/pathology , Male , Mice , Obesity/epidemiology , Obesity/genetics
12.
Arch Neurol ; 69(10): 1303-9, 2012 Oct.
Article in English | MEDLINE | ID: mdl-22801747

ABSTRACT

OBJECTIVE: To determine whether statins affect type 1 interferon responses in relapsing-remitting multiple sclerosis (RRMS). DESIGN: Study effects of atorvastatin on type 1 interferon responses in Jurkat cells, mononuclear cells (MNCs) from therapy-naive patients with RRMS in vitro, and MNCs from interferon-treated RRMS patients in vivo in 4 conditions: no drug, statin only, interferon-beta only, and statin added on to interferon-beta therapy. PATIENTS: The study examined clinically stable patients with RRMS: 21 therapy-naive patients and 14 patients receiving interferon-beta with a statin. INTERVENTIONS: Statin effects on in vitro and in vivo interferon-beta-induced STAT1 transcription factor activation, expression of interferon-stimulated proteins in MNCs, and serum type 1 interferon activity. RESULTS: In vitro, atorvastatin dose dependently inhibited expression of interferon-stimulated P-Y-STAT1 by 44% (P < .001), interferon regulatory factor 1 protein by 30% (P=.006), and myxovirus resistance 1 protein by 32% (P=.004) compared with no-statin control in MNCs from therapy-naive RRMS patients. In vivo, 9 of 10 patients who received high-dose statins (80 mg) had a significant reduction in interferon-beta therapy-induced serum interferon-α/ß activity, whereas only 2 of 4 patients who received medium- dose statins (40 mg) had reductions. High-dose add-on statin therapy significantly blocked interferon-beta function, with less P-Y-STAT1 transcription factor activation, and reduced myxovirus resistance 1 protein and viperin protein production. Medium doses of statins did not change STAT1 activation. CONCLUSIONS: High-dose add-on statin therapy significantly reduces interferon-beta function and type 1 interferon responses in RRMS patients. These data provide a putative mechanism for how statins could counteract the beneficial effects of interferon-beta and worsen disease.


Subject(s)
Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use , Immunologic Factors/therapeutic use , Interferon-beta/therapeutic use , Leukocytes, Mononuclear/drug effects , Multiple Sclerosis/drug therapy , Multiple Sclerosis/pathology , Adult , Dose-Response Relationship, Drug , Enzyme-Linked Immunosorbent Assay , Female , Humans , Immunologic Factors/blood , Immunologic Factors/pharmacology , Interferon Regulatory Factor-1/metabolism , Interferon-beta/blood , Interferon-beta/pharmacology , Jurkat Cells/drug effects , Male , Middle Aged , STAT1 Transcription Factor/metabolism , Signal Transduction/drug effects , Time Factors
13.
Biochem J ; 425(3): 541-51, 2010 Jan 15.
Article in English | MEDLINE | ID: mdl-19903169

ABSTRACT

Chronic hyperglycaemia is detrimental to pancreatic beta-cells by causing impaired insulin secretion and diminished beta-cell function through glucotoxicity. Understanding the mechanisms underlying beta-cell survival is crucial for the prevention of beta-cell failure associated with glucotoxicity. Autophagy is a dynamic lysosomal degradation process that protects organisms against metabolic stress. To date, little is known about the physiological function of autophagy in the pathogenesis of diabetes. In the present study, we explored the roles of autophagy in the survival of pancreatic beta-cells exposed to high glucose using pharmacological and genetic manipulation of autophagy. We demonstrated that chronic high glucose increases autophagy in rat INS-1 (832/13) cells and pancreatic islets, and that this increase is enhanced by inhibition of 5'-AMP-activated protein kinase. Our results also indicate that stimulation of autophagy rescues pancreatic beta-cells from high-glucose-induced cell death and inhibition of autophagy augments caspase-3 activation, suggesting that autophagy plays a protective role in the survival of pancreatic beta-cells. Greater knowledge of the molecular mechanisms linking autophagy and beta-cell survival may unveil novel therapeutic targets needed to preserve beta-cell function.


Subject(s)
AMP-Activated Protein Kinases/metabolism , Autophagy , Glucose/metabolism , Insulin-Secreting Cells/metabolism , Animals , Apoptosis , Caspase 3/metabolism , Cell Proliferation , Cell Survival , Lysosomes/metabolism , Male , Membrane Potentials , Mitochondrial Membranes/metabolism , Rats , Rats, Sprague-Dawley
14.
Oecologia ; 44(1): 44-52, 1979 Dec.
Article in English | MEDLINE | ID: mdl-28310462

ABSTRACT

The structure of a bivoltine, discrete-generation population of Colias philodice eriphyle, occurring in relatively undisturbed habitat, has been examined by mark-release-recapture techniques. The population's general ecology is briefly discussed. Males eclose before females as in other Colias, and a measure of physical wear on adults is related to age of individuals and to the overall position of a sample in the flight period, again as in other Colias. Densities of adults fluctuate drastically, with the first (overwintering) brood always being less dense than the second brood. Dispersal radius of those dispersing does not vary with brood, sex, or year, although the proportion of dispersants does: more males than females disperse in the first brood, while the reverse is true in the second. A tentative behavioral explanation for this is proposed. Adult mortality is unusually high compared to other Colias. The population displays area continuity with adjacent population areas. The Wrightian neighborhood size varies in geographic extent, due to change in dispersant proportions, from 70 to 260 hectares. In adult numbers, it varies from 4-500 (or possibly fewer in very severe first-brood conditions) to upwards of 20,000 in some second broods (though not all adults present always reproduce successfully). Two possible models for the dispersal behavior of Colias are presented. One, the "excited state" model, is so far supported over the other, "continuous activity" model, by the present data and by earlier work on C. alexandra. The adult mortality level is consistent with the conclusion that this population is ecologically marginal for the species. Possible selective pressures preventing further extension of the species' distribution, including possible competition with other Colias, are discussed.

SELECTION OF CITATIONS
SEARCH DETAIL
...